TY - JOUR
T1 - BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer
AU - Darmawi, null
AU - Chen, Lin Yu
AU - Su, Po Hsuan
AU - Liew, Phui Ly
AU - Wang, Hui Chen
AU - Weng, Yu Chun
AU - Huang, Rui Lan
AU - Lai, Hung Cheng
N1 - Funding Information:
Funding: This work was supported by grants from the Ministry of Science and Technology, Taiwan [MOST 110-2314-B-038-058, MOST 109-2314-B-038-052-MY3 to H.-C.L.; MOST 110-2635-B-038-001 to P.-L.L.; MOST 110-2314-B-038-060 to L.-Y.C.; MOST 109-2314-B-038-107-MY3 to P.-H.S.], Taipei Medical University, Taiwan [TMU 108-AE1-B35 to R.-L.H.].
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Endometrial cancer (EC) rates are rising annually. Additional prediction markers need to be evaluated because only 10–20% of EC cases show an objective response to immune-checkpoint inhibitors (ICIs). Our previous methylomic study found that BHLHE22 is hypermethylated in EC tissues and can be detected using a Pap-smear sample. BHLHE22, a basic helix loop helix transcription factor family member, is known as a transcriptional repressor and is involved in cell differentiation. However, the role of BHLHE22 in EC remains poorly understood. Herein, we analyzed BHLHE22 expression in 54 paired cancer and normal endometrial tissue samples, and confirmed with databases (TCGA, GTEx, and human protein atlas). We found that BHLHE22 protein expression was significantly downregulated in EC compared with normal endometrium. High BHLHE22 expression was associated with microsatellite-instable subtype, endometrioid type, grade, and age. It showed a significant favorable survival. BHLHE22 overexpression inhibited the proliferation and migration of EC cells. Functional enrichment analysis showed that BHLHE22 was significantly associated with immune-related pathways. Furthermore, BHLHE22 was positively correlated with proinflammatory leukocyte infiltration and expression of chemokine genes in EC. In conclusion, BHLHE22 regulates immune-related pathways and modulates the immune microenvironment of EC.
AB - Endometrial cancer (EC) rates are rising annually. Additional prediction markers need to be evaluated because only 10–20% of EC cases show an objective response to immune-checkpoint inhibitors (ICIs). Our previous methylomic study found that BHLHE22 is hypermethylated in EC tissues and can be detected using a Pap-smear sample. BHLHE22, a basic helix loop helix transcription factor family member, is known as a transcriptional repressor and is involved in cell differentiation. However, the role of BHLHE22 in EC remains poorly understood. Herein, we analyzed BHLHE22 expression in 54 paired cancer and normal endometrial tissue samples, and confirmed with databases (TCGA, GTEx, and human protein atlas). We found that BHLHE22 protein expression was significantly downregulated in EC compared with normal endometrium. High BHLHE22 expression was associated with microsatellite-instable subtype, endometrioid type, grade, and age. It showed a significant favorable survival. BHLHE22 overexpression inhibited the proliferation and migration of EC cells. Functional enrichment analysis showed that BHLHE22 was significantly associated with immune-related pathways. Furthermore, BHLHE22 was positively correlated with proinflammatory leukocyte infiltration and expression of chemokine genes in EC. In conclusion, BHLHE22 regulates immune-related pathways and modulates the immune microenvironment of EC.
KW - BHLHE22
KW - endometrial cancer
KW - immune infiltrating cells
KW - prognostic
UR - http://www.scopus.com/inward/record.url?scp=85132853965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132853965&partnerID=8YFLogxK
U2 - 10.3390/ijms23137158
DO - 10.3390/ijms23137158
M3 - Article
C2 - 35806162
AN - SCOPUS:85132853965
SN - 1661-6596
VL - 23
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 13
M1 - 7158
ER -
